OAM
AVXL icon

Oxford Asset Management’s Anavex Life Sciences AVXL Stock Holding History

Oxford Asset Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-31,400
Closed -$49K – 1656
2018
Q4 		$49K Buy
+31,400
New +$71.3K ﹤0.01% 1703

Other funds holding AVXL

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Oxford Asset Management's AVXL Position: Q1 2019 in Review

Oxford Asset Management sold out of Anavex Life Sciences (AVXL) in Q1 2019, closing a stake of 31,400 shares — an estimated $49K sold.

Oxford Asset Management first reported a position in AVXL in Q4 2018 and held it in 1 quarter. The position peaked at $49K in Q4 2018. 56 funds tracked by Wall St. Rank hold AVXL as of Q1 2019.

  • Oxford Asset Management reported no remaining Anavex Life Sciences position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 31,400 Anavex Life Sciences shares in Q1 2019, an estimated $49K.
  • Oxford Asset Management first reported a position in Anavex Life Sciences in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's Anavex Life Sciences position peaked at $49K in Q4 2018.
  • 56 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.